Ablynx Plans IPO

Ablynx NV, a Belgium-based drug company focused on a novel class of antibody-derived therapeutic proteins, said that it plans to list on Euronext Brussels later this year, subject to market conditions. J.P. Morgan Securities and KBC Securities will serve as co-lead underwriters. Ablynx has raised